THRD

10.84

0.37% -0.04

Handel nachbörslich: 10.84

Third Harmonic Bio Inc (THRD)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$10.88

Offen:

$10.58

24-Stunden-Volumen:

389.17K

Relative Volume:

1.98

Marktkapitalisierung:

$488.43M

Einnahmen:

Nettoeinkommen (Verlust:

$-32.74M

KGV:

-6.8966

EPS:

-1.5718

Netto-Cashflow:

$-24.89M

1W Leistung:

-3.73%

1M Leistung:

-6.71%

6M Leistung:

-12.16%

1J Leistung:

+1.69%

1-Tages-Spanne:

$10.40

$11.19

1-Wochen-Bereich:

$10.40

$11.88

52-Wochen-Spanne:

$8.075

$16.94

Third Harmonic Bio Inc Stock (THRD) Company Profile

Firmenname

Third Harmonic Bio Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

(209) 727-2457

Adresse

1700 MONTGOMERY STREET, SAN FRANCISCO

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

THRD's Discussions on Twitter

Vergleichen Sie THRD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
THRD Third Harmonic Bio Inc	10.84	488.43M	0	-32.74M	-24.89M	-0.82
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-09	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-06-18	Eingeleitet	Stifel	Buy
2024-06-07	Eingeleitet	Raymond James	Outperform
2022-12-16	Herabstufung	Jefferies	Buy → Hold
2022-12-15	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-10-10	Eingeleitet	Cowen	Outperform
2022-10-10	Eingeleitet	Jefferies	Buy
2022-10-10	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Third Harmonic Bio Inc Aktie (THRD) Neueste Nachrichten

Dec 17, 2024

Long Term Trading Analysis for (THRD) - Stock Traders Daily

Dec 17, 2024

Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise - Investing.com Australia

Dec 17, 2024

Dec 10, 2024

Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress - Investing.com India

Dec 10, 2024

Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress By Investing.com - Investing.com South Africa

Dec 10, 2024

Dec 05, 2024

Atlas Venture Announces $450 Million Fund XIV - Yahoo Finance

Dec 05, 2024

Nov 26, 2024

How the (THRD) price action is used to our Advantage - Stock Traders Daily

Nov 26, 2024

Nov 25, 2024

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference - Marketscreener.com

Nov 25, 2024

Third Harmonic Bio to Present at Evercore HealthCONx Conference in December | THRD Stock News - StockTitan

Nov 25, 2024

Nov 20, 2024

Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade - MSN

Nov 20, 2024

Nov 15, 2024

(THRD) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 15, 2024

RA Capital Management Reduces Stake in Third Harmonic Bio Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Significant Stake Increase by T. Rowe Price in Third Harmonic Bi - GuruFocus.com

Nov 14, 2024

Nov 11, 2024

Vertiv Rises 13% in a Month: Time for Investors to Buy the Stock? - MSN

Nov 11, 2024

Shiba Inu (SHIB) Price Rises 53% but Hits Rejection at Key Ascending Resistance Level - MSN

Nov 11, 2024

Nov 08, 2024

Third Harmonic Bio Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024

Nov 07, 2024